The prevalence of reduced zidovudine susceptibility in zidovudine‐naive, antiretroviral‐experienced HIV‐1‐infected patients

No abstract is available for this paper.

• Publication year

  2003

• Venue

  HIV Medicine

• Publication date

  2003-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1468-1293.2003.00163.xPMID 14525540
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients.

  2002cited by this paper
• Extent of Cross-Resistance between Agents Used To Treat Human Immunodeficiency Virus Type 1 Infection in Clinically Derived Isolates

  2002cited by this paper
• Impact of Stavudine Phenotype and Thymidine Analogues Mutations on Viral Response to Stavudine plus Lamivudine in Altis 2 Anrs Trial

  2001cited by this paper
• Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.

  2000cited by this paper
• XIII International AIDS Conference

  2000cited by this paper
• Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

  2000cited by this paper
• Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine

  2000cited by this paper
• HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort

  2000cited by this paper
• Low-Rate Emergence of Thymidine Analogue Mutations and Multi-Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Gene in Therapy-Naive Patients Receiving Stavudine plus Lamivudine Combination Therapy

  2000cited by this paper
• Emergence of zidovudine resistance in HIV-infected patients receiving stavudine.

  2000cited by this paper
• Mutations in the reverse transcriptase gene of HIV type 1 from subjects after stavudine-didanosine dual therapy.

  2000cited by this paper
• Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

  1999cited by this paper
• Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy

  1999cited by this paper
• Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.

  1999cited by this paper
• HIV-1 Genotypic Resistance Patterns Predict Response to saquinavirritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed

  1999cited by this paper
• Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.

  1999cited by this paper
• Drug-resistant genotyping in HIV-1 therapy

  1999cited by this paper
• A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs

  1998cited by this paper
• Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.

  1998cited by this paper
• Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp.

  1998cited by this paper
• Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Mutations Conferring Resistance to Nucleoside Inhibitors of Reverse Transcriptase: Comparison with Sequence Analysis

  1998cited by this paper
• Efficacy and Tolerability of Stavudine plus Lamivudine in Treatment-Naive and Treatment-Experienced Patients with HIV-1 Infection

  1998cited by this paper
• Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy.

  1997cited by this paper
• Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy.

  1994cited by this paper
• Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing

  1993cited by this paper

• HIV-positive migrants’ experience of living in Sweden

  2020cites this paper
• The Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutation I132M Confers Hypersensitivity to Nucleoside Analogs

  2009cites this paper
• Antiretroviral (ARV) drug resistance in the developing world.

  2007cites this paper
• Genotypic Resistance in HIV-infected Patients Failing a d4T/3TC/NVP Regimen

  2004cites this paper
• Author Index

  2003cites this paper